This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2006 Jul 24;166(14):1446-8.

doi: 10.1001/archinte.166.14.1446.

"Therapeutic intent" in phase 1 oncology trials: a justifiable objective

Maurie Markman¹

Affiliations

PMID: 16864753
DOI: 10.1001/archinte.166.14.1446

Review

"Therapeutic intent" in phase 1 oncology trials: a justifiable objective

Maurie Markman. Arch Intern Med. 2006.

. 2006 Jul 24;166(14):1446-8.

doi: 10.1001/archinte.166.14.1446.

Author

Maurie Markman¹

Affiliation

¹ The University of Texas M. D. Anderson Cancer Center, Mail Box 121, 1515 Holcombe Blvd, Houston, TX 77030, USA. mmarkman@mdanderson.org

PMID: 16864753
DOI: 10.1001/archinte.166.14.1446

No abstract available

PubMed Disclaimer

Comment in

Phase 1 clinical trials: not just for safety anymore?
Khandekar J, Khandekar M. Khandekar J, et al. Arch Intern Med. 2006 Jul 24;166(14):1440-1. doi: 10.1001/archinte.166.14.1440. Arch Intern Med. 2006. PMID: 16864752 No abstract available.

Similar articles

[Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations].
Hanauske AR. Hanauske AR. Med Klin (Munich). 1996 Apr 12;91 Suppl 3:68-70. Med Klin (Munich). 1996. PMID: 8692122 Review. German. No abstract available.
New adaptive method for phase I trials in oncology.
Meille C, Gentet JC, Barbolosi D, André N, Doz F, Iliadis A. Meille C, et al. Clin Pharmacol Ther. 2008 Jun;83(6):873-81. doi: 10.1038/sj.clpt.6100383. Epub 2007 Oct 24. Clin Pharmacol Ther. 2008. PMID: 17957185
Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH. Takimoto CH. Cancer Chemother Pharmacol. 2009 Mar;63(4):703-9. doi: 10.1007/s00280-008-0789-4. Epub 2008 Jul 10. Cancer Chemother Pharmacol. 2009. PMID: 18615251 Review.
Risks and benefits associated with novel phase 1 oncology trial designs.
Koyfman SA, Agrawal M, Garrett-Mayer E, Krohmal B, Wolf E, Emanuel EJ, Gross CP. Koyfman SA, et al. Cancer. 2007 Sep 1;110(5):1115-24. doi: 10.1002/cncr.22878. Cancer. 2007. PMID: 17628485 Review.
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution.
Markman M. Markman M. Cancer. 2007 Oct 15;110(8):1644-7. doi: 10.1002/cncr.22967. Cancer. 2007. PMID: 17879372 No abstract available.

See all similar articles

Cited by

How do researchers decide early clinical trials?
Grankvist H, Kimmelman J. Grankvist H, et al. Med Health Care Philos. 2016 Jun;19(2):191-8. doi: 10.1007/s11019-016-9685-6. Med Health Care Philos. 2016. PMID: 26833467
Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements.
de Melo-Martín I, Sondhi D, Crystal RG. de Melo-Martín I, et al. Mol Ther. 2012 Jun;20(6):1095-102. doi: 10.1038/mt.2012.90. Mol Ther. 2012. PMID: 22652997 Free PMC article. No abstract available.
A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries.
Kimmelman J. Kimmelman J. Trials. 2012 Sep 22;13:173. doi: 10.1186/1745-6215-13-173. Trials. 2012. PMID: 22999017 Free PMC article. Review.
Extending clinical equipoise to phase 1 trials involving patients: unresolved problems.
Anderson JA, Kimmelman J. Anderson JA, et al. Kennedy Inst Ethics J. 2010 Mar;20(1):75-98. doi: 10.1353/ken.0.0307. Kennedy Inst Ethics J. 2010. PMID: 20506695 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems